NCT00491738View on ClinicalTrials.gov

A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2008

Conditions
Renal Cell Carcinoma
Interventions
DRUG

bevacizumab

Intravenous repeating dose

DRUG

sunitinib

Oral repeating dose

DRUG

placebo

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00491738 - A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | Biotech Hunter | Biotech Hunter